Halozyme Therapeutics (HALO) Tops Q3 EPS by 6c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.62 --0%
Revenue Growth %: +37.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
UVV, SII, SCKT, More
Revenue Growth %: +37.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
UVV, SII, SCKT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69. Halozyme Therapeutics sees FY2020 revenue of $250-260 million, versus the consensus of $235.94 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NICE (NICE) Tops Q3 EPS by 6c ; Offers Guidance
- Hecla Mining (HL) Tops Q3 EPS by 7c
- LTC Properties (LTC) Tops Q3 EPS by 22c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
